Phase 4 Hypertension Trial, Recruiting NCT07465913 Sponsor: Eye Centers of Southeast Texas Condition: Hypertension
Back to Hypertension

Phase 4 Hypertension Trial, Recruiting

NCT07465913
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older and have been diagnosed with mild to moderate glaucoma (specifically a type called open-angle glaucoma) affecting both eyes
  • You are currently using 3 eye drop medications for glaucoma, and at least one of them must be a type called a prostaglandin analog (confirm with trial site if unsure which type you use)
  • After a specific laser eye procedure (called DSLT) and a period of stopping your glaucoma medications, your eye pressure in both eyes falls within a certain range (16–36 mmHg) (confirm with trial site)
  • Your vision, when corrected with glasses or contact lenses, meets a minimum level in both eyes (20/60 or better)
  • You are willing and able to give your informed consent to take part in the trial

Who may not be able to join:

  • You have high eye pressure but no actual glaucoma damage
  • You are unable to safely stop your glaucoma eye drop medications for a period before the trial begins
  • You have had a certain type of laser eye treatment (called SLT) within the last 12 months
  • You have previously had glaucoma surgery of any kind (such as trabeculectomy, tube shunt, or certain minimally invasive procedures)
  • Your eye has a narrow or closed drainage angle, as confirmed by a special eye examination
  • You currently have an active eye infection, eye inflammation (uveitis), or severe dry eye
  • You have a cornea condition that makes it difficult to accurately measure eye pressure
  • Your glaucoma is at an advanced stage
  • You have a known allergy or sensitivity to certain medications used in this trial, including Rocklatan or latanoprost
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Eye Centers of Southeast Texas
Registry
ClinicalTrials.gov
Start date
14 May 2026
Est. completion
6 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in mean diurnal intraocular pressure (IOP) from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov